Investor Overview Press Releases October 27, 2026 Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants October 27, 2026 Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma September 3, 2026 Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference View all » Events Oct 27, 20268:00 AM EDT ATI-052 Phase 1b POC Results Update Sep 10, 20262:45 PM EDT 2026 Cantor Global Healthcare Conference Jun 4, 20262:00 PM EDT Jefferies Global Healthcare Conference View all » Feature Presentation August 2026 Corporate Presentation
October 27, 2026 Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
October 27, 2026 Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
September 3, 2026 Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
